Aurobindo Pharma is an Indian pharmaceutical company founded in 1986 that has grown to operate globally with over 70% of revenues from international markets. It has a research and development focus along with manufacturing facilities approved by major regulatory bodies. The company strategy includes gaining market share in segments it enters through collaborative partnerships and alliances while driving bottom line growth. It has a decentralized decision-making structure with accountability across functional areas including research and development, marketing, finance, and corporate social responsibility.
Aurobindo Pharma is an Indian pharmaceutical company founded in 1986 that has grown to operate globally with over 70% of revenues from international markets. It has a research and development focus along with manufacturing facilities approved by major regulatory bodies. The company strategy includes gaining market share in segments it enters through collaborative partnerships and alliances while driving bottom line growth. It has a decentralized decision-making structure with accountability across functional areas including research and development, marketing, finance, and corporate social responsibility.
Aurobindo Pharma is an Indian pharmaceutical company founded in 1986 that has grown to operate globally with over 70% of revenues from international markets. It has a research and development focus along with manufacturing facilities approved by major regulatory bodies. The company strategy includes gaining market share in segments it enters through collaborative partnerships and alliances while driving bottom line growth. It has a decentralized decision-making structure with accountability across functional areas including research and development, marketing, finance, and corporate social responsibility.
Aurobindo Pharma is an Indian pharmaceutical company founded in 1986 that has grown to operate globally with over 70% of revenues from international markets. It has a research and development focus along with manufacturing facilities approved by major regulatory bodies. The company strategy includes gaining market share in segments it enters through collaborative partnerships and alliances while driving bottom line growth. It has a decentralized decision-making structure with accountability across functional areas including research and development, marketing, finance, and corporate social responsibility.
Deeptanshu Pandey 13A1HP015 About the company Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals
Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995.
Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations.
Large manufacturing facilities approved by leading regulatory bodies Strategy It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. Include gaining volume and market shares in every business/segments it enters. Strategy is based on co-working and collaborative alliances and partnerships with global pharmaceutical majors. Driving bottom line growth It is vertically integrated in its manufacturing processes. Structure HR Production R&D Marketi ng Finance Purchase & administration CSR Independent director (4) Wholetime Director (3) Non-executive director (2) Managing director (4) Decision-making is decentralized, with accountability and freedom to operate
CSR committee consist of three or more directors of which, atleast one will be an independent director.
ANIKET PHADKE 13A1HP030 Introduction Headquaters in Mumbai Parent company : Glenmark Pharmaceuticals Limited Subsidary: Glenmark Generics Limited 3 API plants 8 finished dosage plants 3 research facilities
8 Glenmark - Global Footprint 1 API Plant, Gujarat, India 3 Dosage Plants, Goa, India 1 Dosage Plant - Brazil 1 Dosage Plant Czech Republic 1 Dosage Plant, HP, India 1 Dosage Plant, Maharashtra, India R&D for NCEs, India R&D for Generics, India R&D for Biologics, Switzerland Glenmark Generics Ltd., US Glenmark Generics SA, Argentina Medicamenta, Czech Republic Glenmark Farmacetica Ltda., Brazil 2 API Plants, Maharashtra,India Glenmark Generics Europe Limited, London, UK Glenmark Pharma Europe Limited, London, UK Several other subsidiaries and representative offices exist across the world Bowter Bartlett South Arica Glenmark India 1 Dosage Plant - Argentina 9 Glenmark Generics Ltd (GGL) Glenmark Pharmaceuticals Ltd (GPL) Glenmark is divided into two main businesses with different business focus
Leadership
MD and CEO: Glenn Saldanha
Chairman: Glenn Saldanha President: Philip Andrew Gioia
Vision
Global end to end Specialty Company
Global integrated Generic & API leader Wholly owned subsidiary Specialty/Proprietary Generics Glenmark 10 Vision for Glenmark Pharmaceuticals Limited Product Portfolio Launch two proprietary drugs Build late stage pipeline
Market Presence Proprietary product front ends in US, key ROW & European markets
Market Positioning Innovation led company Differentiated branded generic company Invest in building brands Target 2015 Expand into new territories Build differentiated product franchise Global end-to-end Specialty Company Licensing Transition into a proprietary product marketing company 11 Vision for Glenmark Generics Limited (GGL) Product Portfolio 170 generics on the US market 70 generic dossiers for EU markets Over 50 % of revenues from niches
Market Presence Presence in Japan, South Africa & other generic markets Front ends in Japan and key EU markets along with NA
Market Positioning Key Generic Player Preferred supplier of APIs Increase Geographical Reach Target 2015 Expand Niche Product Portfolio Global Integrated Generic & API leader Vertical Integration Amalgamation Glenmark in 2014 has decided for amalgamation of Glenmark Pharmaceuticals Limited and Glenmark Generics Limited (GGL- wholly owned sub. of GPL) Challenges - Two separate entities vision and mission - Brand Dilution - Organisation structure TEVA Satjot Teva pharma Teva is worlds leading generic drug making company. It is engaged in development, production and marketing of generic, specialty and over the counter (OTC) products. Tevas business strategy seeks to capitalize on the growing global need for medicines and evolving market, economic and legislative dynamics. These changes include aging populations, increased spending on pharmaceuticals in emerging market countries, economic pressures on governments and private payors to provide cost-effective healthcare solutions, global evolution in healthcare, legislative reforms, unmet patient needs, an increase in patient awarenessand the growing importance of OTC medicines Strategy Accelerating our growth platforms. Extending our global presence Executing strategic business development Protecting and expanding our core franchises. Reducing our operating costs. Extending our global presence Acquisitions They acquired three-four pharmaceutical companies and also merged with Proctor and gamble and formed PGT which was into consumer health care products. CIPLA Sakshi CIPLA Ltd. Organizational Structure Cipla has incorporated flat organization structure Chairman Director Finance Director Marketing Director Exports Director Research Director HR Technical Director Legal & Secretarial Director Personal care Products CIPLA Ltd. Business Strategies Transformation from a promoter-driven to professional-driven company.
Open to establish partnerships with global companies through product licensing agreements & joint ventures.
New technology investment unit.
To turn existing overseas partnerships into its own entities or subsidiaries through equity deals or joint ventures. Prerna Banga STRATEGY AND APPROACH Focus: Chronic Therapies Differentiation: Technically Complex Products Speed to Market Vertical Integration: Development through Manufacturing to Marketing Optimize Operational Costs Acquisitions yielding high ROI Development of complex generics CREATE SUSTAINABLE REVENUE STREAMS SEEK COST LEADERSHIP BALANCE PROFITABILITY AND INVESTMENTS FOR FUTURE ORGANIZATIONAL STRUCTURE MANAGING DIRECTOR CHAIRMAN OF THE BOARD DIRECTOR DIRECTOR DIRECTOR DIRECTOR EXECUTIVE DIRECTOR SECRETARY EXECUTIVE DIRECTOR SUN PHARMA FOLLOWS A FUNCTIONAL UNITARY STRUCTURE Structured around a CEO and limited Corporate Staff Activities are grouped together by common functions Each functional unit has different set of duties and responsibilities Specialization is built into the organizational structure Optimize Operational Cost Vertical Integration Differentiation Strategy Provides Functional Clarity PRATIK PATEL 13A2HP015 Organizational structure Novartis Transformation 29 Pre- Merger Post- Merger Strategy
Novartis portfolio transformation to focus company on leading businesses and will focus Novartis on leading businesses with innovation power and global scale Pharma, Eye Care and Generics
Novartis swapping assets with GlaxoSmithKline and selling its animal health arm in a bid to simplify its business and increase its focus on high-margin cancer medicines.
Transaction with GSK: acquiring GSK oncology products, divesting Vaccines (excluding flu), and creating Consumer Healthcare joint venture Strengthens Novartis leading Oncology business Positive outcome for OTC by creating Joint Venture where each brand from GSK has >USD 300 million annual sales
Divests Animal Health to Eli Lilly
Wockhardt Satyajeet Managing director Murtaza khorakiwala Chairma n Habil khoraki wala Director Sanjaya baru Director Davinder banu Director Shekhar
Director e Aman mehta
Director R A Shah CIO Executiv e director R&D,Reg ulatory, QA,QC Finance HR Supply chain Organizational structure
Business Strategy Strong collection of revenue from regulated market to boost profit. High margin niche product sales. FTF product launches in the rewarding market. Strong presence in EU market to drive growth. Extensive focus on R&D. Strategic acquisition
LIFE . RESEARCH . HOPE Abhishek Saini Functional structure Slow & inflexible but used IT Suitable for large volume low cost Spread across strategically selected locations Management team expert in their respective fields Thank you
